ALFA FinderBSE filing, NSE: VINEETLAB. Summary written from the filing by ALFA Finder's alert engine.
Vineet Laboratories Ltd: key numbers
- Share price
- ₹37.78
- Market cap
- ₹72.56 Cr
- Revenue (annual)
- ₹59.40 Cr
- Net profit (annual)
- ₹1.11 Cr
- P/E (TTM)
- 22.6×Sector 43.7×
- Promoter holding
- 5.98%+0.00% QoQ
- FII holding
- 0.24%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vineet Laboratories Ltd
All →Vineet Laboratories Q2 FY27 Results: Net Profit ₹0.1 Cr, Down 75.0% YoY
Vineet Laboratories Ltd reported revenue from operations of ₹14.2 Cr (-18.4% YoY) and net profit of ₹0.1 Cr (-75.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹0.1 Cr · -75.0% YoY
Vineet Laboratories Annual Report
Vineet Laboratories filed its FY 2025-26 Annual Report, which marks its turnaround and recapitalisation year. The AGM is scheduled for 30 November 2026.
Vineet Laboratories Annual General Meeting
Vineet Laboratories has circulated notice of its 10th AGM, scheduled for 30 November 2026 via video conferencing. The filing attaches the FY 2025-26 annual report.
Vineet Laboratories Other Announcement
Vineet Laboratories' board appointed SVRL & Co. as statutory auditors, subject to shareholder approval. The five-year term runs from the 10th AGM to the 16th AGM.
Vineet Laboratories Management Change
Vineet Laboratories appointed SVRL & Co. as statutory auditor after NSVR & Associates resigned. Internal, cost and secretarial auditor changes were also approved.
Vineet Laboratories Board Meeting Date
Vineet Laboratories will hold a board meeting on 4 November 2026 to approve the 10th AGM notice and FY2025-26 Directors' Report. The filing is an advance notice; the agenda is proposed only.
Other other announcement announcements
All →Religare Enterprises Other Announcement
Religare Enterprises filed CARE Ratings' monitoring agency report for the quarter ended September 30, 2026, on its Rs 1,500 crore preferential warrant issue. The report states proceeds were used per the offer document with no deviation.
Optivalue Tek Consulting Other Announcement
Optivalue Tek filed Acuité's half-yearly monitoring report on IPO proceeds for H1 FY2026-27. No deviation from the offer objects was observed.
5Paisa Capital Other Announcement
5paisa Capital Ltd filed its quarterly shareholding pattern under Regulation 31(1)(c). It reports routine holding figures with no new transaction or corporate event.
Chennai Meenakshi Multispeciality Hospital Other Announcement
Chennai Meenakshi Multispeciality Hospital issued a duplicate share certificate for 100 shares to Inder Chand Kothari L under folio 00008717. The intimation is routine share-certificate paperwork with no transaction or money involved.
Axel Polymers Other Announcement
Axel Polymers reports no deviation in utilisation of its Rs 11.18 Crore preferential issue proceeds for the quarter ended 30 September 2026. This is a routine Regulation 32 statement of deviation with a clean auditor certificate.
360 One Wam Other Announcement
360 ONE WAM disclosed PIT sales by five insiders on 12 November 2026, totalling about Rs 3.55 Crore. The sellers are designated persons, KMP and an employee's relative, with no promoter involved.
- Value
- ₹3.55 Cr